About atovaquone + progunail
Antimalarial combination
Used for
- Prevention of malaria
- Treatment of uncomplicated falciparum malaria
Usual adult dose
Prevention: one adult tablet daily, starting 1–2 days before exposure, continuing until seven days afterward. Treatment: four adult tablets daily for three days.
Usual dose in children
Prevention, daily pediatric tablets: 11–20 kg, one; 21–30 kg, two; 31–40 kg, three. Treatment dosing is weight-based.
Common side effects
- Nausea, vomiting, or diarrhea
- Stomach pain
- Headache
- Dizziness
Important warnings
- Take with food or a milky drink.
- Repeat dose if vomiting occurs within one hour.
- Not suitable for severe malaria.
- Not used for prevention with severely reduced kidney function.
Pregnancy
Generally avoided during pregnancy because safety information is limited; use requires assessment of benefits and risks.
Breastfeeding
Not recommended when breastfeeding an infant weighing less than 5 kg because safety information is limited.
Interactions
- Rifampicin and rifabutin reduce atovaquone levels.
- Metoclopramide reduces atovaquone absorption.
- Warfarin effects may increase, requiring closer monitoring.
- Tetracycline can reduce atovaquone levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.